MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-07-04
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as MK-0646, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing.
PURPOSE: This phase I/II trial is studying the side effects and best dose of MK-0646 when
given together with etoposide and cisplatin and to see how well it works in treating patients
with extensive-stage small cell lung cancer.